Adding Atezolizumab to mFOLFOX6 Improves DFS Among Patients with Stage III dMMR Colon Cancer By Ogkologos - March 31, 2026 72 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATOMIC study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR ¿Pueden confundirse los síntomas del cáncer con la menopausia? November 1, 2022 FDA Approves Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable NSCLC September 18, 2024 EMA Recommends Extension of Indications for Ibrutinib September 11, 2025 EMA Recommends Extending Indications for Pembrolizumab to Patients with Advanced Biliary... December 1, 2023 Load more HOT NEWS Stealing Strategies from Cancerous T Cells May Boost Immunotherapy Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with... 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Lung... The Largest Randomised Study to Date Points to Low Ipsilateral Breast...
